Eurazeo (ENXTPA:RF) Cut Its Half Year Loss, Is The Stock A Bargain?
Why Eurazeo’s latest half year results matter for investors
Eurazeo (ENXTPA:RF) drew fresh attention after half year results to June 30, 2026 reported sales of €211.44 million and a net loss of €6.34 million, compared with a much larger loss a year earlier.
See our latest analysis for Eurazeo.
The earnings release appears to have shifted sentiment around Eurazeo, with a 19.17% 1 month share price return and a 7.64% 7 day share price return contrasting with a year to date share price decline of 4.89%. The 1 year total shareholder return is slightly negative and the 5 year total shareholder return remains materially lower.
If this earnings move has you reassessing opportunities in financials and beyond, it could be a good moment to broaden your search using the 104 top founder-led companies
Eurazeo’s share price has moved higher while the gap between the current €49.60 price and analyst targets near €69.17 remains wide. So where might fair value sit within that range as the valuation work begins?
Most Popular Narrative: 31.6% Undervalued
The most followed narrative on Eurazeo sees fair value at €72.50 compared with the latest €49.60 close, which is a wide gap for investors to weigh.
Eurazeo's asset management segment is experiencing dynamic growth, with fundraising up 23% and management fees from third parties increasing by 14%. This suggests potential future revenue growth due to higher fee-paying assets under management (AUM).
Want to understand why this narrative backs such a large gap to today’s price? The story hinges on rapid revenue expansion, rising margins and a very specific profit multiple assumption.
Result: Fair Value of €72.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Eurazeo’s story still hinges on successful exits from legacy assets and on write downs not worsening, since either could quickly challenge this upbeat valuation case.
Find out about the key risks to this Eurazeo narrative.
Next Steps
Unsure whether this Eurazeo narrative feels too optimistic or too cautious? Look at the numbers, weigh the trade offs and shape your own view with the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Eurazeo?
If Eurazeo has sharpened your focus, do not stop here. Use Simply Wall Street's screener to spot fresh ideas before the crowd moves on them.
- Target resilience by reviewing companies in the 302 resilient stocks with low risk scores that may better align with your appetite for steadier returns.
- Hunt for quality at a reasonable price by scanning the 253 high quality undervalued stocks that match your preferred fundamentals and valuation filters.
- Strengthen your income stream by comparing opportunities in the 441 dividend fortresses that could complement a long term portfolio focus on payouts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com